<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55759">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380248</url>
  </required_header>
  <id_info>
    <org_study_id>EXI639-P001 (C-13-040)</org_study_id>
    <nct_id>NCT02380248</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects</brief_title>
  <official_title>Clinical Evaluation of Systane® Gel Drops on Corneal Staining in Indian Subjects With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Systane® Gel Drops in
      dry eye subjects following 90 days of QID (4 times/day) dosing. This study will be conducted
      in India.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in corneal staining at all study time points</measure>
    <time_frame>Baseline (Day 0), Up to Day 90</time_frame>
    <description>Corneal staining will be assessed by the Investigator through slit-lamp examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops</intervention_name>
    <arm_group_label>Systane</arm_group_label>
    <other_name>Systane® Gel Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give informed consent, and be willing and able to attend all study visits.

          -  Best-corrected visual acuity (BCVA) of ≥ 55 letters in each eye as measured by ETDRS
             (letters read method).

          -  Dry eye in both eyes diagnosed by an ophthalmologist.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential who are pregnant, test positive on a pregnancy test,
             or breast-feeding.

          -  Any medical condition (systemic or ophthalmic) that may, in the opinion of the
             Investigator, preclude the safe administration of test article or safe participation
             in the study.

          -  Any contraindications or hypersensitivities to the study medications or their
             components.

          -  Ocular surgery (of any type, including PRK, LASIK, Epilasik, etc.) or ocular trauma
             requiring medical or pharmacological treatment within 1 year of Screening.

          -  Use of topical ocular prescription or non-prescription medications, RESTASIS or
             topical ocular steroids within 14 days of Screening.

          -  Chronic medications (over the counter, prescription, or vitamins) that have not been
             on a stable dose for at least 30 days prior to Screening.

          -  Contact lens wear within 1 week of Screening and/or unwillingness to discontinue
             contact lens wear for the duration of the study.

          -  Participation in any other clinical trial within 30 days prior to Screening.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head, CTM, Med Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Laboratories Pvt Ltd (India)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sr. Clinical Manager, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon India for Trial Locations</name>
      <address>
        <city>Karnataka</city>
        <zip>560048</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 27, 2016</lastchanged_date>
  <firstreceived_date>March 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
